Intravascular stent having high fatigue performance

Information

  • Patent Grant
  • 10575973
  • Patent Number
    10,575,973
  • Date Filed
    Wednesday, April 11, 2018
    7 years ago
  • Date Issued
    Tuesday, March 3, 2020
    5 years ago
Abstract
The invention is directed to an expandable stent for implantation in a body lumen, such as an artery, and a method for making it from a single length of tubing. The stent consists of a plurality of radially expandable cylindrical elements generally aligned on a common axis and interconnected by one or more links. A Y-shaped member comprised of a link and a U-shaped member has relief dimples formed in the curved portion of a valley to reduce localized stress and thereby reduce fatigue failure that can lead to link structure failure.
Description
BACKGROUND

This invention relates to expandable endoprosthesis devices, generally called stents, which are adapted to be implanted into a patient's body lumen, such as blood vessel, to maintain the patency thereof. These devices are very useful in the treatment of atherosclerotic stenosis in blood vessels.


Various means have been described to deliver and implant stents. One method frequently described for delivering a stent to a desired intraluminal location includes mounting the expandable stent on an expandable member, such as a balloon, provided on the distal end of an intravascular catheter, advancing the catheter to the desired location within the patient's body lumen, inflating the balloon on the catheter to expand the stent into a permanent expanded condition and then deflating the balloon and removing the catheter.


The stent must be able to satisfy a number of mechanical requirements. First, the stent must be capable of withstanding the structural loads, namely radial compressive forces, imposed on the stent as it supports the wall of a vessel. Therefore, a stent must possess adequate radial strength. Radial strength, which is the ability of a stent to resist radial compressive forces, is due to strength and rigidity around the circumferential direction of the stent. Radial strength and rigidity, therefore, may also be described as, hoop or circumferential strength and rigidity.


Once expanded, the stent must adequately maintain its size and shape throughout its service life despite the various forces that may come to bear on it, including the cyclic loading induced by the beating heart. For example, a radially directed force may tend to cause a stent to recoil inward. Generally, it is desirable to minimize recoil.


In addition, the stent must possess sufficient flexibility to allow for crimping, expansion, and cyclic loading. Longitudinal flexibility is important to allow the stent to be maneuvered through a tortuous vascular path and to enable it to conform to a deployment site that may not be linear or may be subject to flexure. Finally, the stent must be biocompatible so as not to trigger any adverse vascular responses.


The structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements. The scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed so that the stent can be radially compressed (to allow crimping) and radially expanded (to allow deployment). A conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other.


Additionally, a medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier that includes an active or bioactive agent or drug. Polymeric scaffolding may also serve as a carrier of an active agent or drug.


Furthermore, it may be desirable for a stent to be biodegradable. In many treatment applications, the presence of a stent in a body may be necessary for a limited period of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. Therefore, stents fabricated from biodegradable, bioabsorbable, and/or bioerodable materials such as bioabsorbable polymers should be configured to completely erode only after the clinical need for them has ended.


Along with crimping and expansion forces, implanting a stent in the dynamic environment in a curved artery section causes stresses in the stent structure that can result in fatigue failure. This fatigue failure is particularly acute in stents formed from a polymer material.


What has been needed and heretofore unavailable is a stent formed from a polymer material and modified in critical structural areas where cyclical loads are concentrated, and fatigue stresses are constant in order to improve the fatigue performance of the stent.


SUMMARY OF THE INVENTION

The present invention is directed to an expandable stent which is relatively flexible along its longitudinal axis to facilitate delivery through tortuous body lumens, but which has structural features to improve fatigue performance of the stent.


The stent of the invention generally includes a plurality of radially expandable cylindrical elements or rings which are relatively independent in their ability to expand and to flex relative to one another. Interconnecting elements or links extending between adjacent cylindrical rings provide increased stability and prevent warping of the stent upon the expansion thereof. The resulting stent structure is a series of radially expandable cylindrical rings which are spaced longitudinally close enough so that small dissections in the wall of a body lumen may be pressed back into position against the lumenal wall, but not so close as to compromise the longitudinal flexibility of the stent.


Each of the cylindrical rings making up the stent has a proximal end and a distal end and a cylindrical plane defined by a cylindrical outer wall surface that extends circumferentially between the proximal end and the distal end of the cylindrical ring. Generally the cylindrical rings have a serpentine or undulating shape which includes at least one U-shaped element, and typically each ring has more than one U-shaped element. The cylindrical rings are interconnected by at least one link which attaches one cylindrical ring to an adjacent cylindrical ring. The combination of the rings and links allows the stent to be highly flexible along its longitudinal axis.


Not only do the links that interconnect the cylindrical rings provide flexibility to the stent, but the positioning of the links also enhances the flexibility by allowing uniform flexibility when the stent is bent in any direction along its longitudinal axis. Uniform flexibility along the stent derives in part from the links of one ring being circumferentially offset from the links in an adjacent ring. Further, the cylindrical rings are configured to provide flexibility to the stent in that portions of the rings can flex or bend as the stent is delivered through a tortuous vessel.


The cylindrical rings typically are formed of a plurality of peaks and valleys, where the valleys of one cylindrical ring are in phase with the valleys of an adjacent cylindrical ring. In this configuration, at least one link attaches each cylindrical ring to an adjacent cylindrical ring so that at least a portion of the link is positioned within one of the valleys and it attaches the valley to an adjacent peak.


While the cylindrical rings and links generally are not separate structures, they have been conveniently referred to as rings and links for ease of identification. Further, the cylindrical rings can be thought of as comprising a series of U's, W's and Y-shaped structures in a repeating pattern. Again, while the cylindrical rings are not divided up or segmented into U's, W's and Y's, the pattern of the cylindrical rings resemble such configurations. The U's, W's and Y's promote flexibility in the stent primarily by flexing as the stent is delivered through a tortuous vessel.


The radial expansion of the expandable ring deforms the undulating pattern thereof similar to changes in a waveform which result in decreasing the waveform's amplitude. Preferably, the undulating patterns of the individual cylindrical structures are in phase with each other in order to prevent the contraction of the stent along its length when it is expanded. The cylindrical structures of the stent are plastically deformed when expanded (except with NiTi alloys) so that the stent will remain in the expanded condition, therefore they must be sufficiently rigid when expanded to prevent the collapse thereof in use.


The links which interconnect adjacent cylindrical rings should have a transverse cross-section similar to the transverse dimensions of the undulating components of the expandable cylindrical rings. The links may be formed in a unitary structure with the expandable cylindrical rings from the same intermediate product, such as a tubular element. Preferably, all of the links of a stent are joined at either the peaks or the valleys of the undulating structure of the cylindrical rings which form the stent. In this manner, there is no shortening of the stent upon expansion.


The number and location of the links interconnecting adjacent cylindrical rings can be varied in order to develop the desired longitudinal flexibility in the stent structure both in the unexpanded as well as the expanded condition. These properties are important to minimize alteration of the natural physiology of the body lumen into which the stent is implanted and to maintain the compliance of the body lumen which is internally supported by the stent. Generally, the greater the longitudinal flexibility of the stent, the easier and the more safely it can be delivered to the implantation site.


In one embodiment, the Y-shaped members are formed by the link attaching to a curved portion of a valley, which then resembles the Y-shaped member. In this embodiment, there is a gradual radius on each side of the link where it connects to the curved portion of the Y-shaped member. More specifically, a smooth and gradual transition radius extends from each side of the link to the curved portion of the Y-shaped member, the radius being in the range from 0.017 to 0.022 inch (0.44 to 0.55 mm). One preferred radius is 0.019 inch (0.50 mm). These gradual and smooth transition radii provide a more ridged and stiffer scaffold area resulting in improved link structural fatigue performance.


In another embodiment, the Y-shaped members are formed by the links attaching to a curved portion of a valley, which then resembles the Y-shaped member. In this embodiment, the curved portion of the valley has a width that is less than the width of the curved portion of the peaks forming the U-shaped members. In one embodiment, the width of the curved portion of the valley of the Y-shaped member is in the range from 0.0073 to 0.0066 inch (0.185 to 0.168 mm). In one preferred embodiment, the width of the curved portion of the valley of the Y-shaped member is 0.0068 inch (0.173 mm). This Y-shaped member provides a reduced width which will experience less stress during fatigue loading, and hence result in improved Y-shaped member structural fatigue performance.


In another embodiment, the Y-shaped members are formed by the links attaching to a curved portion of a valley, which then resembles the Y-shaped member. In this embodiment, relief dimples are formed in the curved portion of the valley where the link attaches to the curved portion. Link fatigue factures can occur at the end of a straight strut segment near the link and valley junction where the material is highly stressed during fatigue loading and fatigue strength is lower due to the axially oriented material being weaker. The purpose of introducing relief dimples on the curved portion of the valley is to shift the location of this highly stressed area more into the curved portion of the valley where the circumferentially oriented material is stronger and can withstand more stress, thereby improving structural fatigue performance.


Other features and advantages of the present invention will become more apparent from the following detailed description of the invention, when taken in conjunction with the accompanying exemplary drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is an elevational view, partially in section, of a stent embodying features of the invention which is mounted on a delivery catheter and disposed within a damaged artery.



FIG. 2 is an elevational view, partially in section, similar to that shown in FIG. 1 wherein the stent is expanded within a damaged artery, pressing the damaged lining against the arterial wall.



FIG. 3 is an elevational view, partially in section showing the expanded stent within the artery after withdrawal of the delivery catheter.



FIG. 4 is a perspective view of a stent embodying features of the invention in an unexpanded state, with one end of the stent being shown in an exploded view illustrate the details thereof.



FIG. 5 is a plan view of a flattened section of a stent of the invention which illustrates the undulating pattern of the stent shown in FIG. 4.



FIG. 6 is a plan view of a flattened section of a stent illustrating an alternate undulating pattern in which the expandable cylindrical elements of the stent which are out of phase.



FIG. 7 is an enlarged partial view of the stent of FIG. 5 with the various members slightly expanded.



FIG. 8 is an enlarged partial view of a Y-shaped member depicting a smooth and gradual transition radius from the link to the curved portion of the Y-shaped member.



FIGS. 9A-9C are enlarged partial views depicting a Y-shaped member having a narrow width through the curved portion of the Y-shaped member.



FIG. 10 is an enlarged partial view depicting a Y-shaped member having relief dimples in the curved portions of the Y-shaped member.



FIG. 11 is an enlarged partial view depicting a Y-shaped member having relief dimples and reversed radii associated with the dimples.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


FIG. 1 illustrates a prior art stent 10 which is mounted onto a delivery catheter 11. The stent generally comprises a plurality of radially expandable cylindrical rings 12 disposed generally coaxially and interconnected by links 13 disposed between adjacent cylindrical rings. The delivery catheter 11 has an expandable portion or balloon 14 for expanding of the stent 10 within an artery 15.


The delivery catheter 11, onto which the stent 10 is mounted, is similar to a conventional balloon dilatation catheter used for angioplasty procedures.


Each radially expandable cylindrical ring 12 of the stent 10 may be independently expanded. Therefore, the balloon 14 may be provided with an inflated shape other than cylindrical, e.g. tapered, to facilitate implantation of the stent 10 in a variety of body lumen shapes.


The delivery of the stent 10 is accomplished in the following manner. The stent 10 is first mounted onto the inflatable balloon 14 on the distal extremity of the delivery catheter 11. The balloon 14 is slightly inflated to secure the stent 10 onto the exterior of the balloon. The catheter-stent assembly is introduced within the patient's vasculature in a conventional Seldinger technique through a guiding catheter (not shown). A guidewire 18 is disposed across an arterial section and then the catheter-stent assembly is advanced over a guidewire 18 within the artery 15 until the stent 10 is positioned in the area to be repaired. The balloon 14 of the catheter 11 is expanding the stent 10 against the artery 15, which is illustrated in FIG. 2. While not shown in the drawing, the artery 15 is preferably expanded slightly by the expansion of the stent 10 to seat or otherwise fix the stent 10 to prevent movement. In some circumstances, during the treatment of stenotic portions of an artery, the artery may have to be expanded considerably in order to facilitate passage of blood or other fluid there through.


The stent 10 serves to hold open the artery 15 after the catheter 11 is withdrawn, as illustrated by FIG. 3. Due to the formation of the stent 10 from an elongated tubular member, the undulating component of the cylindrical rings of the stent 10 is relatively flat in transverse cross-section, so that when the stent is expanded, the cylindrical rings are pressed slightly into the wall of the artery 15, and as a result, do not interfere with the blood flow through the artery 15. The cylindrical rings 12 of stent 10 which are pressed into the wall of the artery 15 will eventually be covered with endothelial cell growth which further minimizes blood flow interference. The undulating portion of the cylindrical rings 12 provide good tacking characteristics to prevent stent movement within the artery. Furthermore, the closely spaced cylindrical rings 12 at regular intervals provide uniform support for the wall of the artery 15.



FIG. 4 is an enlarged perspective view of the prior art stent 10 shown in FIG. 1 with one end of the stent shown in an exploded view to illustrate in greater detail the placement of links 13 between adjacent radially expandable cylindrical rings. Each pair of the links 13 on one side of a cylindrical ring 12 are preferably placed to achieve maximum flexibility for a stent. As shown in FIGS. 4 and 5, the stent 10 has three links 13 between adjacent radially expandable cylindrical rings 12 which are 120 degrees apart. Each pair of links 13 on one side of a cylindrical element 12 are offset radially 60 degrees from the pair on the other side of the cylindrical ring. The alternation of the links results in a stent which is longitudinally flexible in essentially all directions. Various configurations for the placement of links are possible. All of the links of an individual stent should be secured to either peaks 16 or valleys 17 of the undulating structural rings in order to prevent shortening of the stent during expansion thereof.


The properties of the stent 10 may also be varied by alteration of the undulating pattern of the cylindrical rings 12. FIG. 6 illustrates an alternative prior art stent structure in which the cylindrical rings are in serpentine patterns but out of phase with adjacent cylindrical rings. The particular pattern and how many undulations per unit of length around the circumference of the cylindrical rings 12, or the amplitude of the undulations, are chosen to fill particular mechanical requirements for the stent such as radial stiffness.


The number of undulations may also be varied to accommodate placement of links 13, e.g., at the peaks of the undulations as shown in FIGS. 5 and 6.


As shown in FIG. 7, a portion of the prior art stent 10 is slightly expanded to illustrate the expansion of the cylindrical rings 12, which are in the form of a serpentine pattern 30. As previously mentioned, each cylindrical ring 12 is connected by links 13. Serpentine pattern 30 is made up of a plurality of U-shaped members 31, W-shaped members 32, and Y-shaped members 33, each having a different radius so that expansion forces are more evenly distributed over the various members.


The underlying structure or substrate of a stent can be completely or at least in part made from a biodegradable polymer or combination of biodegradable polymers, a biostable polymer or combination of biostable polymers, or a combination of biodegradable and biostable polymers. Additionally, a polymer-based coating for a surface of a device can be a biodegradable polymer or combination of biodegradable polymers, a biostable polymer or combination of biostable polymers, or a combination of biodegradable and biostable polymers.


A stent may be fabricated from a polymeric tube or a sheet by rolling and bonding the edges to form a tube. A stent pattern may be formed on a polymeric tube by laser cutting a pattern on the tube. Representative examples of lasers that may be used include, but are not limited to, excimer, carbon dioxide, and YAG. In other embodiments, chemical etching may be used to form a pattern on a tube.


The pattern of a stent can vary throughout its structure to allow radial expansion and compression and longitudinal flexure. A pattern may include portions of struts that are straight or relatively straight, or some patterns may include bending elements. The bending elements can comprise free bending elements, W-shaped bending elements, and Y-shaped bending elements. Bending elements that have a U-shape are free bending elements. The free bending elements are not directly connected to any adjacent ring, whereas each W-shaped bending element is directly connected by one of the links at a concave portion of the apex of the W-shaped bending element to a convex portion of an apex on an adjacent ring located in a direction of a first end of a scaffold, and each Y-shaped bending element is directly connected by one of the links at a convex portion of the apex of the Y-shaped bending element to a concave portion of an apex on an adjacent ring located in a direction of a second end of the scaffold.


Bending elements bend inward when a stent is crimped to allow radial compression. Bending elements also bend outward when a stent is expanded to allow for radial expansion. After deployment, a stent is under static and cyclic compressive loads from the vessel walls. Thus, bending elements are subjected to deformation during use. “Use” includes, but is not limited to, manufacturing, assembling (e.g., crimping stent on a catheter), delivery of stent into and through a bodily lumen to a treatment site, and deployment of stent at a treatment site, and treatment after deployment.


As indicated above, a stent has certain mechanical requirements. A stent must have sufficient radial strength to withstand structural loads, namely radial compressive forces, imposed on the stent as it supports the walls of a vessel. In addition, the stent must possess sufficient flexibility to allow for crimping, expansion, and cyclic loading. Also, a sufficiently low profile is important to deliver the stent to the treatment site.


Polymers tend to have a number of shortcomings for use as materials for stents. One such shortcoming is that many biodegradable polymers have a relatively low modulus, and thus relatively low radial strength. Compared to metals, the strength to weight ratio of polymers is smaller than that of metals. A polymeric stent with inadequate radial strength can result in mechanical failure or recoil inward after implantation into a vessel. To compensate for the relatively low modulus, a polymeric stent requires significantly thicker struts than a metallic stent, which results in an undesirably large profile.


Another shortcoming of polymers is that many polymers, such as biodegradable polymers, tend to be brittle under physiological conditions or conditions within a human body. Specifically, such polymers can have a Tg, which is defined below, above human body temperature which is approximately 37° C. These polymer systems exhibit a brittle fracture mechanism in which there is little or no plastic deformation prior to failure. As a result, a stent fabricated from such polymers can have insufficient toughness for the range of use of a stent. In particular, it is important for a stent to be resistant to fracture throughout the range of use of a stent, i.e., crimping, delivery, deployment, and during a desired treatment period.


The “glass transition temperature,” Tg, is the temperature at which the amorphous domains of a polymer change from a brittle vitreous state to a solid deformable or ductile state at atmospheric pressure. In other words, the Tg corresponds to the temperature where the onset of segmental motion in the chains of the polymer occurs. When an amorphous or semicrystalline polymer is exposed to an increasing temperature, the coefficient of expansion and the heat capacity of the polymer both increase as the temperature is raised, indicating increased molecular motion. As the temperature is raised, the actual molecular volume in the sample remains constant, and so a higher coefficient of expansion points to an increase in free volume associated with the system and therefore increases freedom for the molecules to move. The increasing heat capacity corresponds to an increase in heat dissipation through movement. Tg of a given polymer can be dependent on the heating rate and can be influenced by the thermal history of the polymer. Furthermore, the chemical structure of the polymer heavily influences the glass transition by affecting mobility.


Other potential problems with polymeric stents include creep, stress relaxation, and physical aging. Creep refers to the gradual deformation that occurs in a polymeric construct subjected to an applied load. It is believed that the delayed response of polymer chains to stress during deformation causes creep behavior. Creep occurs even when the applied load is constant. Creep can cause an expanded stent to retract radially inward, reducing the effectiveness of a stent in maintaining desired vascular patency. The rate at which polymers creep depends not only on the load, but also on temperature. In general, a loaded construct creeps faster at higher temperatures.


Stress relaxation is also a consequence of delayed molecular motions as in creep. Contrary to creep, however, which is experienced when the load is constant, stress relaxation occurs when deformation (or strain) is constant and is manifested by a reduction in the force (stress) required to maintain a constant deformation


Physical aging, as used herein, refers to densification in the amorphous regions of a semi-crystalline polymer. Physical aging of semi-crystalline polymers that have glass transition temperatures (Tg) above their normal storage temperature, which, for the purposes of this invention is room temperature, i.e., from about 15° C. to about 35° C., occurs primarily through the phenomenon known as densification. Densification occurs when polymer chains rearrange in order to move from a non-equilibrium state to an equilibrium state. The reordering of polymer chains tends to increase the modulus of the polymer resulting in a brittle or more brittle polymer.


Thus, physical aging results in an increase in brittleness of a polymer which can result in cracking of struts upon crimping and deployment. Since physical aging results from densification of amorphous regions of a polymer, an increase in crystallinity can reduce or inhibit physical aging.


However, it is well known by those skilled in the art that the mechanical properties of a polymer can be modified through various processing techniques, such as by applying stress to a polymer. James L. White and Joseph E. Spruiell, Polymer and Engineering Science, 1981, Vol. 21, No. 13. The application of stress can induce molecular orientation along the direction of stress which can modify mechanical properties along the direction of applied stress. For example, strength and modulus are some of the important properties that depend upon orientation of polymer chains in a polymer. Molecular orientation refers to the relative orientation of polymer chains along a longitudinal or covalent axis of the polymer chains.


A polymer may be completely amorphous, partially crystalline, or almost completely crystalline. A partially crystalline polymer includes crystalline regions separated by amorphous regions. The crystalline regions do not necessarily have the same or similar orientation of polymer chains. However, a high degree of orientation of crystallites may be induced by applying stress to a semi-crystalline polymer. The stress may also induce orientation in the amorphous regions. An oriented amorphous region also tends to have high strength and high modulus along an axis of alignment of polymer chains. Additionally, for some polymers under some conditions, induced alignment in an amorphous polymer may be accompanied by crystallization of the amorphous polymer into an ordered structure. This is known as stress induced crystallization.


As indicated above, due to the magnitude and directions of stresses imposed on a stent during use, it is important for the mechanical stability of the stent to have suitable mechanical properties, such as strength and modulus in both the axial and circumferential directions. Therefore, it can be advantageous to modify the mechanical properties of a tube, to be used in the fabrication of a stent, by induced orientation from applied stress in the axial direction, circumferential direction, or both. Since highly oriented regions in polymers tend to be associated with higher strength and modulus, it may be desirable to incorporate processes that induce alignment of polymer chains along one or more preferred axes or directions into fabrication of stents.


In keeping with the invention shown in FIG. 8, the Y-shaped members 40 are formed by the links 42 attaching to a curved portion 44 of a valley 46, which then resembles the Y-shaped member 40. In this embodiment, there is a gradual radius R1 and R2 on each side of the link where it connects to the curved portion of the Y-shaped member. More specifically, a smooth and gradual transition radius R1 and R2 extends from each side of the link to the curved portion of the Y-shaped member, the radius R1 or R2 being in the range from 0.017 to 0.022 inch (0.44 to 0.55 mm). One preferred radius is 0.019 inch (0.50 mm). This gradual and smooth transition radius provides a more rigid and stiffer scaffold area which will undergo less displacement during fatigue loading resulting in improved link structural fatigue performance. Further, the stiffer Y-transition could develop additional material orientation through crimping resulting in higher material strength in the region.


In another embodiment as shown in FIG. 9A, the Y-shaped members 40 are formed by the link 42 attaching to a curved portion 44 of a valley 46, which then resembles the Y-shaped member 40. In this embodiment, the curved portion 44 of the valley 46 has a width 48 that is less than a width 50 of the curved portion 52 of the peaks 54 forming the U-shaped members (not shown). In one embodiment, the width 48 of the curved portion of the valley of the Y-shaped member is in the range from 0.0073 to 0.0066 inch (0.185 to 0.168 mm). In one preferred embodiment, the width of the curved portion of the valley of the Y-shaped member is 0.0068 inch (0.173 mm). The width 50 of the curved portion 52 is 0.0075 inch (0.1905 mm). This Y-shaped member is highly flexible and will experience less stress during fatigue loading, and hence result in improved Y-shaped member structural fatigue performance.


In FIG. 9B, a first shaded area 70 represents the curved portion 72 of the link 74 as it transitions into the curved portion 75 of the valley 76 of the Y-shaped member 78. In one embodiment, the first shaded area 70 is 0.00003 inch2 (0.02 mm2). In FIG. 9C, a second shaded area 80 represents a straight portion 82 of the link 84 plus the curved portion 86 of the link as it transitions into the curved portion 85 of the valley 88 of the Y-shaped member 90. In one embodiment, the second shaded area 80 is 0.00012 inch2 (0.08 mm2). Both the first shaded area 70 and the second shaded area 80 represent structural features that provide less stress in the shaded areas during fatigue loading, resulting in improved Y-shaped member 78, 88 structural fatigue performance.


In another embodiment as shown in FIG. 10, the Y-shaped members 40 are formed by the link 42 attaching to a curved portion 44 of a valley 46, which then resembles the Y-shaped member 40. In this embodiment, relief dimples 60 are formed at the curved portion 44 of the valley 46 where the link 42 attaches to the curved portion. Link fatigue factures can occur at the end of a straight section near the link and valley junction where the axially orientated material is weaker and is highly stressed during fatigue loading. The purpose of introducing relief dimples 60 on the curved portion 44 of the valley 46 is to shift the location of this highly stressed area more into the curved portion of the valley where the circumferentially oriented material is stronger and can withstand more stress, thereby improving structural fatigue performance. In the embodiment shown in FIG. 11, the relief dimples 60 have a radius R3 in range of 0.00197 inch (0.05 mm) to 0.00276 inch (0.07 mm). In one embodiment, the relief dimples have a radius R3 of 0.00236 inch (0.06 mm). A reverse radius R4 of 0.000079 inch (0.02 mm) is on either side of the relief dimples in order to have a smooth transition of the relief dimples 60 on the curved portion 44 of valley 46.


While the invention has been illustrated and described herein in terms of its use as an intravascular stent for treating coronary arteries, it will be apparent to those skilled in the art that the stent can be used in other instances such as in treating peripheral vessels. Other modifications and improvements may be made without departing from the scope of the invention.


Other modifications and improvements can be made to the invention without departing from the scope thereof.

Claims
  • 1. A longitudinally flexible stent for implanting in a body lumen, comprising: a first cylindrical ring, a second cylindrical ring, a third cylindrical ring, up to an Nth cylindrical ring, the cylindrical rings being generally independently expandable in the radial direction and generally aligned on a common longitudinal axis;each of the cylindrical rings having an undulating pattern of peaks and valleys, the undulating pattern of each of the cylindrical rings being in phase with the undulating pattern of each of the adjacent cylindrical rings;each of the cylindrical rings being interconnected by links to one of the adjacent cylindrical rings so that the cylindrical rings form a longitudinally flexible stent; anda Y-shaped member is formed by one of the links connecting to a curved portion of valley, a first relief dimple and a second relief dimple are formed in the curved portion of the valley and wherein the first dimple and the second dimple have a radius R3 in the range consisting of 0.00197 inch to 0.00276 inch.
  • 2. The stent of claim 1, wherein a reverse radius R4 is located on either side of the first relief dimple and the second relief dimple thereby providing a smooth transition of the relief dimples on the curved portion of the valley.
  • 3. The stent of claim 2, wherein the reversed radius R4 is 0.000079 inch.
  • 4. The stent of claim 1, wherein the distance between adjacent cylindrical rings is less than the width of either a single peak or a single valley.
  • 5. The stent of claim 1, wherein each of the cylindrical rings includes at least three peaks and three valleys.
  • 6. The stent of claim 1, wherein the peaks and valleys have a U-shaped configuration.
  • 7. The stent of claim 1, wherein the stent is formed from a polymer material.
  • 8. The stent of claim 1, wherein the stent is formed from a biodegradable material.
US Referenced Citations (339)
Number Name Date Kind
2070073 Walton Feb 1937 A
2701559 Cooper Feb 1955 A
2854982 Pagano Oct 1958 A
2854983 Baskin Oct 1958 A
3105492 Jeckel Oct 1963 A
3155095 Brown Nov 1964 A
3284762 Kompanek Nov 1966 A
3334629 Cohn Aug 1967 A
3420142 Gale et al. Jan 1969 A
3526005 Bokros et al. Sep 1970 A
3540431 Mobin-Uddin Nov 1970 A
3562820 Braun Feb 1971 A
3599641 Sheridan Aug 1971 A
3657744 Ersek Apr 1972 A
3713175 Weisman Jan 1973 A
3714671 Goodenough et al. Feb 1973 A
3774596 Cook Nov 1973 A
3834394 Hunter et al. Sep 1974 A
3858441 Comeau Jan 1975 A
3868956 Alfidi et al. Mar 1975 A
3874388 King Apr 1975 A
3882845 Bucalo May 1975 A
3889685 Miller, Jr. et al. Jun 1975 A
3893344 Dantlgraber et al. Jul 1975 A
3894974 Hunter Jul 1975 A
3952747 Kimmell, Jr. Apr 1976 A
3968800 Vilasi Jul 1976 A
3993078 Bergentz et al. Nov 1976 A
4038702 Sawyer Aug 1977 A
4047252 Liebig et al. Sep 1977 A
4056854 Boretos et al. Nov 1977 A
4061134 Samuels et al. Dec 1977 A
4065816 Sawyer Jan 1978 A
4076285 Martinez Feb 1978 A
4080706 Heilman et al. Mar 1978 A
4105022 Antoshkiw et al. Aug 1978 A
4106129 Carpentier et al. Aug 1978 A
4130904 Whalen Dec 1978 A
4140126 Choudhury Feb 1979 A
4159719 Haerr Jul 1979 A
4183102 Guiset Jan 1980 A
4190909 Ablaza Mar 1980 A
4195637 Gleichner et al. Apr 1980 A
4198982 Fortner et al. Apr 1980 A
4214587 Sakura Jul 1980 A
RE30434 Davis Nov 1980 E
4264419 Pryor Apr 1981 A
4276132 Fettel et al. Jun 1981 A
4295464 Shihata Oct 1981 A
4299226 Banka Nov 1981 A
4300244 Bokros Nov 1981 A
4313231 Koyamada Feb 1982 A
4319363 Ketharanathan Mar 1982 A
4323071 Simpson et al. Apr 1982 A
4323994 Coogler Apr 1982 A
4328811 Fogarty May 1982 A
4338942 Fogarty Jul 1982 A
4340046 Cox Jul 1982 A
4343048 Ross et al. Aug 1982 A
4343049 Fettel et al. Aug 1982 A
4387952 Slusher Jun 1983 A
4390599 Broyles Jun 1983 A
4402307 Hanson et al. Sep 1983 A
4403612 Fogarty Sep 1983 A
4448195 Leveen et al. May 1984 A
4479497 Fogarty et al. Oct 1984 A
4483340 Fogarty et al. Nov 1984 A
4493711 Chin et al. Jan 1985 A
4494531 Gianturco Jan 1985 A
4503569 Dotter Mar 1985 A
4504354 George et al. Mar 1985 A
4512338 Balko et al. Apr 1985 A
4516972 Samson May 1985 A
4531933 Norton et al. Jul 1985 A
4550447 Seiler, Jr. et al. Nov 1985 A
4553545 Maass et al. Nov 1985 A
4560374 Hammerslag Dec 1985 A
4562596 Kornberg Jan 1986 A
4572186 Gould et al. Feb 1986 A
4577631 Kreamer Mar 1986 A
4580568 Gianturco Apr 1986 A
4586505 Sisson et al. May 1986 A
4604762 Robinson Aug 1986 A
4616652 Simpson Oct 1986 A
4617932 Kornberg Oct 1986 A
4619246 Molgaard-Nielsen et al. Oct 1986 A
4619261 Guerriero Oct 1986 A
4641653 Rockey Feb 1987 A
4643184 Mobin-Uddin Feb 1987 A
4647416 Seiler, Jr. et al. Mar 1987 A
4649922 Wiktor Mar 1987 A
4650466 Luther Mar 1987 A
4655771 Wallsten Apr 1987 A
4660559 McGregor et al. Apr 1987 A
4660560 Klein Apr 1987 A
4665918 Garza et al. May 1987 A
4670734 Caddock Jun 1987 A
4673409 Van Kampen Jun 1987 A
4676241 Webb et al. Jun 1987 A
4680031 Alonso Jul 1987 A
4681110 Wiktor Jul 1987 A
4699611 Bowden Oct 1987 A
4704126 Baswell et al. Nov 1987 A
4705517 Dipisa, Jr. Nov 1987 A
4706671 Weinrib Nov 1987 A
4710181 Fuqua Dec 1987 A
4723549 Wholey et al. Feb 1988 A
4731054 Billeter et al. Mar 1988 A
4733665 Palmaz Mar 1988 A
4739762 Palmaz Apr 1988 A
4740207 Kreamer Apr 1988 A
4748982 Horzewski et al. Jun 1988 A
4760849 Kropf Aug 1988 A
4762128 Rosenbluth Aug 1988 A
4767418 Deininger et al. Aug 1988 A
4768507 Fischell et al. Sep 1988 A
4771773 Kropf Sep 1988 A
4771777 Horzewski et al. Sep 1988 A
4775426 Murley et al. Oct 1988 A
4776337 Palmaz Oct 1988 A
4787899 Lazarus Nov 1988 A
4793348 Palmaz Dec 1988 A
4794928 Kletschka Jan 1989 A
4795458 Regan Jan 1989 A
4800882 Gianturco Jan 1989 A
4813925 Anderson, Jr. et al. Mar 1989 A
4823814 Drogendijk et al. Apr 1989 A
4830003 Wolff et al. May 1989 A
4842575 Hoffman, Jr. et al. Jun 1989 A
4848343 Wallsten et al. Jul 1989 A
4856516 Hillstead Aug 1989 A
4869714 Deininger et al. Sep 1989 A
4870966 Dellon et al. Oct 1989 A
4875480 Imbert Oct 1989 A
4877030 Beck et al. Oct 1989 A
4878906 Lindemann et al. Nov 1989 A
4886062 Wiktor Dec 1989 A
4887997 Okada Dec 1989 A
4892539 Koch Jan 1990 A
4892541 Alonso Jan 1990 A
4893623 Rosenbluth Jan 1990 A
4902289 Yannas Feb 1990 A
4907336 Gianturco et al. Mar 1990 A
4913141 Hillstead Apr 1990 A
4921479 Grayzel May 1990 A
4922905 Strecker May 1990 A
4923464 Dipisa, Jr. May 1990 A
4943346 Mattelin Jul 1990 A
4950227 Savin et al. Aug 1990 A
4954126 Wallsten Sep 1990 A
4963022 Sommargren Oct 1990 A
4969458 Wiktor Nov 1990 A
4969890 Sugita et al. Nov 1990 A
4986831 King et al. Jan 1991 A
4988356 Crittenden et al. Jan 1991 A
4990155 Wilkoff Feb 1991 A
4994032 Sugiyama et al. Feb 1991 A
4994071 MacGregor Feb 1991 A
4994077 Dobben Feb 1991 A
4998539 Delsanti Mar 1991 A
4998923 Samson et al. Mar 1991 A
5002560 Machold et al. Mar 1991 A
5007926 Derbyshire Apr 1991 A
5015253 MacGregor May 1991 A
5019085 Hillstead May 1991 A
5019090 Pinchuk May 1991 A
5026377 Burton et al. Jun 1991 A
5034001 Garrison et al. Jul 1991 A
5035706 Giantureo et al. Jul 1991 A
5037377 Alonso Aug 1991 A
5037392 Hillstead Aug 1991 A
5037427 Harada et al. Aug 1991 A
5041126 Gianturco Aug 1991 A
5059211 Stack et al. Oct 1991 A
5061273 Yock Oct 1991 A
5061275 Wallsten et al. Oct 1991 A
5062829 Pryor et al. Nov 1991 A
5064435 Porter Nov 1991 A
5071407 Termin et al. Dec 1991 A
5073694 Tessier et al. Dec 1991 A
5078720 Burton et al. Jan 1992 A
5078726 Kreamer Jan 1992 A
5078736 Behl Jan 1992 A
5084065 Weldon et al. Jan 1992 A
5089005 Harada Feb 1992 A
5089006 Stiles Feb 1992 A
5092877 Pinchuk Mar 1992 A
5100429 Sinofsky et al. Mar 1992 A
5102417 Palmaz Apr 1992 A
5104399 Lazarus Apr 1992 A
5104404 Wolff Apr 1992 A
5108416 Ryan et al. Apr 1992 A
5108417 Sawyer Apr 1992 A
5116318 Hillstead May 1992 A
5116360 Pinchuk et al. May 1992 A
5116365 Hillstead May 1992 A
5122154 Rhodes Jun 1992 A
5123917 Lee Jun 1992 A
5133732 Wiktor Jul 1992 A
5135536 Hillstead Aug 1992 A
5158548 Lau et al. Oct 1992 A
5161547 Tower Nov 1992 A
5163951 Pinchuk et al. Nov 1992 A
5163952 Froix Nov 1992 A
5163958 Pinchuk Nov 1992 A
5171262 MacGregor Dec 1992 A
5180368 Garrison Jan 1993 A
5183085 Timmermans Feb 1993 A
5192297 Hull Mar 1993 A
5192307 Wall Mar 1993 A
5192311 King et al. Mar 1993 A
5195984 Schatz Mar 1993 A
5197978 Hess Mar 1993 A
5201901 Harada et al. Apr 1993 A
5217482 Keith Jun 1993 A
5222971 Willard et al. Jun 1993 A
RE34327 Kreamer Jul 1993 E
5226913 Pinchuk Jul 1993 A
5234456 Silvestrini Aug 1993 A
5236447 Kubo et al. Aug 1993 A
5242394 Tremulis Sep 1993 A
5242399 Lau et al. Sep 1993 A
5242452 Inoue Sep 1993 A
5266073 Wall Nov 1993 A
5275622 Lazarus et al. Jan 1994 A
5282823 Schwartz et al. Feb 1994 A
5282824 Gianturco Feb 1994 A
5282848 Schmitt Feb 1994 A
5290295 Querals et al. Mar 1994 A
5290305 Inoue Mar 1994 A
5292331 Boneau Mar 1994 A
5304200 Spaulding Apr 1994 A
5306286 Stack et al. Apr 1994 A
5314444 Gianturco May 1994 A
5314472 Fontaine May 1994 A
5330500 Song Jul 1994 A
5342348 Kaplan Aug 1994 A
5344426 Lau et al. Sep 1994 A
5354308 Simon et al. Oct 1994 A
5354309 Schnepp-Pesch et al. Oct 1994 A
5356433 Rowland et al. Oct 1994 A
5360401 Turnland et al. Nov 1994 A
5368566 Crocker Nov 1994 A
5372600 Beyar et al. Dec 1994 A
5378239 Termin et al. Jan 1995 A
5382261 Palmaz Jan 1995 A
5383892 Cardon et al. Jan 1995 A
5397345 Lazarus Mar 1995 A
5405378 Strecker Apr 1995 A
5411552 Andersen et al. May 1995 A
5421955 Lau et al. Jun 1995 A
5423745 Todd et al. Jun 1995 A
5423885 Williams Jun 1995 A
5443496 Schwartz et al. Aug 1995 A
5445646 Euteneuer et al. Aug 1995 A
5449373 Pinchasik et al. Sep 1995 A
5456694 Marin et al. Oct 1995 A
5458615 Klemm et al. Oct 1995 A
5476476 Hillstead Dec 1995 A
5484449 Amundson et al. Jan 1996 A
5507767 Maeda et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5514154 Lau et al. May 1996 A
5527336 Rosenbluth et al. Jun 1996 A
5545132 Fagan Aug 1996 A
5549635 Solar Aug 1996 A
5549663 Cottone, Jr. Aug 1996 A
5554181 Das Sep 1996 A
5556413 Lam Sep 1996 A
5562728 Lazarus et al. Oct 1996 A
5569295 Lam Oct 1996 A
5571135 Fraser et al. Nov 1996 A
5591197 Orth et al. Jan 1997 A
5591198 Boyle et al. Jan 1997 A
5603721 Lau et al. Feb 1997 A
5618299 Khosravi et al. Apr 1997 A
5618301 Hauenstein et al. Apr 1997 A
5626604 Cottone May 1997 A
5653690 Booth et al. Aug 1997 A
5653691 Rupp et al. Aug 1997 A
5653727 Wiktor Aug 1997 A
5669936 Lazarus Sep 1997 A
5674278 Boneau Oct 1997 A
5707386 Schnepp-Pesch et al. Jan 1998 A
5716396 Williams, Jr. Feb 1998 A
5718713 Frantzen Feb 1998 A
5720726 Marcadis et al. Feb 1998 A
5725570 Heath Mar 1998 A
5728158 Lau et al. Mar 1998 A
5733303 Israel et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735893 Lau et al. Apr 1998 A
5755771 Penn et al. May 1998 A
5755776 Al-Saadon May 1998 A
5759192 Saunders Jun 1998 A
5766238 Lau et al. Jun 1998 A
5776161 Globerman Jul 1998 A
5780807 Saunders Jul 1998 A
5782855 Lau et al. Jul 1998 A
5800509 Boneau Sep 1998 A
5800521 Orth Sep 1998 A
5800526 Anderson et al. Sep 1998 A
5810871 Tuckey et al. Sep 1998 A
5817152 Birdsall et al. Oct 1998 A
5830217 Ryan Nov 1998 A
5833699 Chuter Nov 1998 A
5836964 Richter et al. Nov 1998 A
5836965 Jendersee et al. Nov 1998 A
5843120 Israel et al. Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5843175 Frantzen Dec 1998 A
5868782 Frantzen Feb 1999 A
5879381 Moriuchi et al. Mar 1999 A
5879382 Boneau Mar 1999 A
5891190 Boneau Apr 1999 A
5893852 Morales Apr 1999 A
5902332 Schatz May 1999 A
5911732 Hojeibane Jun 1999 A
5913897 Corso, Jr. et al. Jun 1999 A
5925061 Ogi et al. Jul 1999 A
5935162 Dang Aug 1999 A
5972018 Israel et al. Oct 1999 A
5980553 Gray et al. Nov 1999 A
5984964 Roberts et al. Nov 1999 A
5997468 Wolff et al. Dec 1999 A
6030413 Lazarus Feb 2000 A
6056776 Lau et al. May 2000 A
6066167 Lau et al. May 2000 A
6066168 Lau et al. May 2000 A
6146358 Rowe Nov 2000 A
6309412 Lau et al. Oct 2001 B1
6344053 Boneau Feb 2002 B1
6432133 Lau et al. Aug 2002 B1
6485511 Lau et al. Nov 2002 B2
6511504 Lau et al. Jan 2003 B1
20040133271 Jang Jul 2004 A1
20110238157 Li et al. Sep 2011 A1
20120065724 Jang Mar 2012 A1
Foreign Referenced Citations (3)
Number Date Country
1477137 Nov 2004 EP
2017042329 Mar 2017 WO
WO-2017042329 Mar 2017 WO
Non-Patent Literature Citations (2)
Entry
WO2017042329A1—Translation (Year: 2017).
International Search Report, ISA/US dated May 8, 2019, pp. 1-2.
Related Publications (1)
Number Date Country
20190314174 A1 Oct 2019 US